The official opening ceremony of AstraZeneca’s Northern China Headquarters was held in Beijing Economic-Technological Development Area on May 28, 2021. The new establishment marks the first step of the company’s China regional headquarters strategy in 2021.

The new headquarters, located in the Beijing Economic-Technological Development Area (BDA) and backed by the Beijing Municipal Government and the government of the BDA, will oversee the company’s operation, management and marketing in North and Northeast China, including Beijing and Tianjin.

AstraZeneca’s Northern China Headquarters will focus on industries related to smart medicine and technology, as well as the use of innovative technologies in the biomedicine and healthcare industries. With the company’s Northern China Headquarters commencing full operation, the Community Intelligence Healthcare Innovation Center, the Beijing International Life Science Innovation Campus and the AstraZeneca Global R&D China Beijing Office will also be established in the BDA.

Given the external uncertainty of the post-pandemic era, China is focused on the coordinated regional development to drive domestic economic growth. To help the country achieve this goal, AstraZeneca is bringing premium medical resources to grassroots medical institutions and helping to build a number of regional healthcare innovation industry clusters by moving forward its regional headquarters strategy in China.